Theravance Biopharma Inc. (NASDAQ: TBPH) stock gained by 0.85% at last close whereas the TBPH stock price fell by 25.19% during after-hours trading. Theravance Biopharma is a pharmaceutical firm that specializes in the research, development, and marketing of organ-specific medications. Its goal is to usher in a new generation of small molecule medicines that are more suited to patient requirements.
>> 7 Top Picks for the Post-Pandemic Economy <<
What’s happening with TBPH Stock?
Izencitinib, an orally given, gut-selective pan-Janus kinase (JAK) inhibitor under development for the cure of ulcerative colitis, had positive top-line findings from its Phase 2b dose-finding induction trial, according to Theravance Biopharma.
When it comes to discovering hidden gems within the stock market, Stock Wire News has consistently provided invaluable insights. Stock Wire News invites you to explore their upcoming Wealth Building Report. This report will shine a spotlight on little-known companies with the potential for substantial growth in 2024, and it's completely FREE for a limited time.
Claim the free report now by clicking here and start discovering the hidden gems of the market
Sponsored
Read More
- Looking For The Best Stocks To Buy For 2021? 3 Electric Vehicle Stocks To Watch
- Top 3 Cosmetics Stocks in the market
The primary objective of change in the total Mayo score, as well as the critical secondary target of clinical remission at week 8, were not met in comparison to placebo. The modified Mayo score showed a slight daily dosage rise in patient adherence, which was led by a decrease in rectal bleeding.
Moreover,
Izencitinib was well accepted at all dosages when given orally once daily for 8 weeks; adverse event rates were comparable between izencitinib and placebo participants. In individuals using izencitinib, there were no cases of perforation, opportunistic infection, severe cardiovascular or thromboembolic events, complex zoster, or non-melanoma skin cancer. In comparison to placebo, there were no significant changes in lab results such as creatine phosphokinase and lipids in patients using izencitinib. Izencitinib plasma exposure was minimal, which was expected for a gut-selective medication.
Rick E Winningham, Chief Executive Officer, TBPH Stock stated,
After eight weeks of therapy with izencitinib in ulcerative colitis, they had great hopes for the Phase 2b trial. They noticed in the Phase 1b research with only four weeks of therapy, albeit in a limited number of patients, the completeness and consistency of a wide range of medical, histologic, and biomarker results. They intend to examine the data in order to truly comprehend the findings and the possibilities for optimizing gut-selective medication as a therapy for inflammatory bowel disease patients. They thank everyone who took part in this clinical trial, which they hope to have top-line findings in late the fourth quarter of 2021 or early the first quarter of 2022.